Jupiter Asset Management Ltd. reduced its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 319,446 shares of the biotechnology company's stock after selling 32,531 shares during the quarter. Jupiter Asset Management Ltd. owned 1.18% of Arcturus Therapeutics worth $5,421,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of ARCT. Sumitomo Mitsui Trust Group Inc. increased its position in Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock valued at $52,819,000 after buying an additional 712,650 shares in the last quarter. Geode Capital Management LLC grew its position in Arcturus Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company's stock valued at $12,810,000 after buying an additional 5,789 shares during the period. Empire Life Investments Inc. increased its stake in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock worth $4,742,000 after purchasing an additional 128,771 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Arcturus Therapeutics by 5.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock valued at $3,526,000 after buying an additional 10,180 shares in the last quarter. Finally, Royce & Associates LP lifted its holdings in Arcturus Therapeutics by 18.3% during the third quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company's stock valued at $3,616,000 after purchasing an additional 24,085 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on ARCT shares. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. HC Wainwright reduced their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group lowered their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $59.20.
Check Out Our Latest Stock Report on ARCT
Arcturus Therapeutics Trading Up 0.6 %
Shares of Arcturus Therapeutics stock traded up $0.08 during trading on Monday, reaching $14.16. The company's stock had a trading volume of 290,131 shares, compared to its average volume of 458,143. The company has a 50-day moving average price of $16.64 and a two-hundred day moving average price of $18.29. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $12.75 and a fifty-two week high of $45.00. The firm has a market cap of $384.02 million, a PE ratio of -6.38 and a beta of 2.96.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The business had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.
About Arcturus Therapeutics
(
Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Read More
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
